Description
Carfizome 60mg Injection is a targeted therapy used in the treatment of certain types of cancer. Its active ingredient is Carfilzomib, a proteasome inhibitor. Carfilzomib works by blocking the action of proteasomes, which are protein complexes within cells that break down unwanted or damaged proteins. In cancer cells, particularly in multiple myeloma, these proteasomes are crucial for their survival and proliferation. By inhibiting proteasomes, Carfizome disrupts the normal functioning of cancer cells, leading to their death. It is primarily indicated for patients with relapsed or refractory multiple myeloma who have received at least one prior therapy. The dosage and administration of Carfizome 60mg Injection should be strictly determined by a qualified healthcare professional based on the patient’s condition and response. Common side effects may include fatigue, anemia, thrombocytopenia, dyspnea, and hypertension. Patients should be monitored closely for potential adverse reactions. Carfizome 60mg Injection should be stored as per the manufacturer’s instructions, typically refrigerated and protected from light.
